LFMD LifeMD, Inc. : Bullish and Bearish Analyst Opinions
Sentiment & Price
▼
Sentiment Gauge
2
Bull
0
Bear
0
Watch
Bull 100%
Bear 0%
Price & Sentiment
long
short
neutral
— click post dots to open
Loading chart...
Recent News
Top Views ▼
No recent news for LFMD
No theses available
Feed
14:00
Apr 25
Apr 25
LFMD has pharmacy and FDA catalyst.
LFMD is a better peptide play than Hims because they own a pharmacy that can compound drugs. The July 23 FDA approval for compound peptides is a major catalyst; if approved, LFMD could see a massive price spike due to its infrastructure to produce compound peptides.
HIGH
22:21
Apr 24
Apr 24
LFMD huge upside on FDA approval.
LFMD owns a pharmacy that can compound peptides. The FDA is meeting on July 23 to decide on compound peptide approval. If approved, LFMD will see a massive move (like Intel's recent 22% day) because they have the infrastructure to produce and distribute compound peptides, unlike larger competitors.
HIGH
About LFMD Analyst Coverage
Buzzberg tracks LFMD (LifeMD, Inc.) across 1 sources. 2 bullish vs 0 bearish calls from 2 analysts. Sentiment: predominantly bullish (100%). 2 total trade ideas tracked.